PharmaCyte Biotech Officers to Attend Annual Meeting of the American Society of Clinical Oncology
June 03 2016 - 8:20AM
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage
biotechnology company focused on developing targeted treatments for
cancer and diabetes using its signature live-cell encapsulation
technology, Cell-in-a-Box®, today announced that its entire senior
management team will attend the American Society of Clinical
Oncology’s (ASCO) 52nd annual meeting to be held June 3-7, 2016, at
McCormick Place in Chicago. The theme of this year’s meeting is
“Collective Wisdom – The Future of Patient Centered Care and
Research.”
Kenneth L. Waggoner, the Chief Executive Officer of PharmaCyte
Biotech, stated, “This year’s ASCO annual meeting will be
invaluable as we head into the final preparations for our Phase 2b
clinical trial in advanced pancreatic cancer. During ASCO we will
host a medical and scientific discussion of our therapy for
advanced pancreatic cancer among top oncologist investigators who
have expressed interest in PharmaCyte’s technology and
participation in our clinical trial. Joining me will be Dr. Gerald
W. Crabtree, Dr. Matthias Löhr, Dr. Manuel Hidalgo, Prof. Dr.
Walter H. Günzburg, Dr. Brian Salmons and Dr. Sanjay Batra.
Presentations will be made by our Chief Scientific Officer, Dr.
Günzburg, and Dr. Salmons - the co-developers of our Cell-in-a-Box®
live cell encapsulation technology. Presentations will also be made
by Dr. Löhr and Dr. Hidalgo. Dr. Löhr is the Chairman of our
Medical and Scientific Advisory Board (Board) and was the Principal
Investigator of the two earlier clinical trials where our
technology was found to be safe and effective in treating advanced
pancreatic cancer. Dr. Hidalgo is a member of the Board and one of
the principal architects of the design of our clinical trial.”
ASCO is one of the largest organizations in the
world devoted to the advancement of treatments for all types of
cancer, and its annual meeting is the one of the largest
educational and scientific meetings in the world. Over 32,000
individuals from around the globe have registered for this year’s
meeting with over 50% of these from outside the United States. More
than 26,000 of the total number of registrants are oncology
professionals. Approximately 6,000 abstracts of presentations have
been submitted for consideration by ASCO. At this meeting, reports
of studies on all types of cancer will be presented. For
PharmaCyte, presentations on advanced pancreatic cancer and
clinical trials will be of paramount importance.
In addition to scientists and clinicians,
representatives from large and small pharmaceutical and biotech
companies and Contract Research Organizations, all with an interest
in cancer, will be in attendance. ASCO’s annual meeting
provides representatives from all areas of the cancer spectrum the
opportunity to interact and offers an unparalleled opportunity for
the free exchange of information among meeting attendees.
About PharmaCyte BiotechPharmaCyte Biotech is a
clinical stage biotechnology company developing and preparing to
commercialize treatments for cancer and diabetes based upon a
proprietary cellulose-based live cell encapsulation technology
known as “Cell-in-a-Box®.” This technology will be used as a
platform upon which treatments for several types of cancer and
diabetes are being developed. PharmaCyte’s treatment for cancer
involves encapsulating genetically modified live cells that convert
an inactive chemotherapy drug into its active or “cancer-killing”
form. These encapsulated live cells are placed as close to a
cancerous tumor as possible. Once implanted in a patient, a
chemotherapy drug which needs to be activated in the body
(ifosfamide) is then given intravenously at one-third the normal
dose. The ifosfamide is carried by the circulatory system to where
the encapsulated cells have been placed. When the ifosfamide, which
is normally activated in the liver, comes in contact with the
encapsulated live cells, activation of the chemotherapy drug takes
place at the source of the cancer without any side effects from the
chemotherapy. This “targeted chemotherapy” has proven remarkably
effective and safe to use in past clinical trials.
In addition to developing a novel treatment for
cancer, PharmaCyte is developing a treatment for Type 1 diabetes
and insulin-dependent Type 2 diabetes. PharmaCyte plans to
encapsulate a human cell line that has been genetically engineered
to produce, store and release insulin in response to the levels of
blood sugar in the human body. The encapsulation will be done using
the Cell-in-a-Box® technology.
Safe Harbor This press release may contain
forward-looking statements regarding PharmaCyte Biotech and its
future events and results that involve inherent risks and
uncertainties. The words "anticipate", "believe", "estimate",
"expect", "intend", "plan" and similar expressions, as they relate
to PharmaCyte or its management, are intended to identify
forward-looking statements. Important factors, many of which are
beyond the control of PharmaCyte, could cause actual results to
differ materially from those set forth in the forward-looking
statements. They include PharmaCyte's ability to continue as a
going concern, delays or unsuccessful results in preclinical and
clinical trials, flaws or defects regarding its product candidates,
changes in relevant legislation or regulatory requirements,
uncertainty of protection of PharmaCyte’s intellectual property and
PharmaCyte’s continued ability to raise capital. PharmaCyte does
not assume any obligation to update any of these forward-looking
statements.
More information about PharmaCyte Biotech can be
found at www.PharmaCyte.com. It can also be obtained by contacting
Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com